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OBJECTIVES The purpose of this study was to evaluate the effects of the angiotensin-converting enzyme
(ACE) inhibitor imidapril and the calcium antagonist amlodipine on endothelial function
before and after 2, 4, 8, 12, 24 and 48 weeks of treatment.
BACKGROUND There are limited data on whether and how long endothelial function is improved after
initiation of ACE inhibitor treatment and how the grade of endothelial function further
progresses after improvement of endothelial dysfunction in patients with essential hyperten-
sion.
METHODS The forearm blood flow (FBF) was measured in 25 patients with essential hypertension and
in 25 normotensive subjects by using strain-gauge plethysmography during reactive hyper-
emia (RH) (280 mm Hg for 5 min) and after sublingual administration of nitroglycerin
(NTG, 0.3 mg).
RESULTS The FBF of patients with essential hypertension during RH was significantly less than that
of normotensive subjects. The increase in FBF after sublingual NTG was similar in both
groups. Both imidapril (n 5 13) and amlodipine (n 5 12) significantly reduced systolic blood
pressure and diastolic after eight weeks of treatment from the pretreatment values. Forearm
vascular resistance was significantly decreased after two weeks of treatment. Imidapril
significantly augmented RH after 12 weeks of treatment from the pretreatment values
(31.6 6 5.7 to 38.2 6 6.0 ml/min per 100 ml tissue, p , 0.05), whereas amlodipine did not
alter RH for each treatment period. The ability of imidapril to improve RH was maintained
throughout the 48-week treatment period. There was no significant difference in RH at 12,
24 and 48 weeks. The increase in FBF after sublingual administration of NTG was similar
in all treatment periods for the two groups. The infusion of NG-monomethyl-L-arginine, a
nitric oxide (NO) synthase inhibitor, abolished the enhancement of RH in hypertensive
patients treated with imidapril.
CONCLUSIONS These findings suggest that the ACE inhibitor imidapril augments RH after 12 weeks of
treatment in patients with essential hypertension and that this ACE inhibitor-induced
augmentation of RH may be due to an increase in NO. (J Am Coll Cardiol 2001;37:863–70)
© 2001 by the American College of Cardiology
Endothelium plays an important role in the regulation of
vascular tone by producing various vasoactive factors, in-
cluding vasodilating substances such as nitric oxide (NO),
prostacyclin and endothelium-derived hyperpolarizing fac-
tor (EDHF) and vasoconstricting substances such as endo-
thelin, angiotensin II, thromboxane A2 and prostaglandin
H2 (1–4). The endothelium is both a target of and a
contributor to hypertension. Hypertension is associated
with alterations in the resistance vessels’ endothelial func-
tion. We and other investigators have reported that endo-
thelial function is impaired in patients with essential hyper-
tension (5–10).
Several lines of evidence have shown that the impaired
endothelial function of brachial (11), renal (12) and small
arteries (13) of patients with essential hypertension can be
restored by long-term treatment with angiotensin-
converting enzyme (ACE) inhibitors. Recently, we also
have shown that a 12-week treatment period with the ACE
inhibitor imidapril improves endothelium-dependent reno-
vascular relaxation in patients with essential hypertension
(14,15). These findings are supported by the results of
animal studies using ACE inhibitors (16–18). These ben-
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eficial effects of ACE inhibitors on endothelial function are
thought to increase NO activity through the inhibition of
angiotensin II–mediated production of superoxide, which
inactivates NO (19), along with inhibition of bradykinin
degradation, which mediates NO production (20). Creager
et al. (21), however, reported that antihypertensive treat-
ment for up seven to eight weeks with ACE inhibitors, such
as captopril and enalapril, did not augment endothelium-
dependent vasodilation in the forearm circulation of hyper-
tensive patients. There is little information on whether and
how long endothelial function is improved after initiation of
ACE inhibitor treatment and how the grade of endothelial
function further progresses after improvement of endothe-
lial dysfunction in patients with essential hypertension.
Thus, we evaluated the effects of the ACE inhibitor
imidapril and the calcium antagonist amlodipine on endo-
thelial function before and after 2, 4, 8, 12, 24 and 48 weeks
of treatment in patients with essential hypertension. For this
purpose, we measured the responses of forearm blood flow
(FBF) to reactive hyperemia (RH), an index of
endothelium-dependent vasodilation, and sublingually ad-
ministered nitroglycerin (NTG), an index of endothelium-
independent vasodilation.
METHODS
Subjects. We studied 25 Japanese patients with essential
hypertension (15 men and 10 women; mean age 53 6 10
years) and 25 normotensive subjects (14 men and 11
women; mean age 48 6 12 years). Hypertension was
defined as systolic blood pressure (BP) .160 mm Hg
and/or diastolic BP .95 mm Hg, in a sitting position, on at
least three different occasions. Patients with secondary
forms of hypertension were excluded on the basis of a
complete history, physical examination, radiologic and ul-
trasound examinations, urinalysis, plasma renin activity,
concentrations of plasma aldosterone, norepinephrine, se-
rum creatinine, potassium, calcium and free thyroxine and
24-h urinary excretion of 17-hydroxycorticosteroids, 17-
ketogenic steroids and vanillylmandelic acid. None of the
patients had a history of cardiovascular or cerebrovascular
disease, diabetes mellitus, liver disease or renal disease.
Normotension was defined as systolic BP ,130 mm Hg and
diastolic BP ,80 mm Hg. The normotensive control
subjects had no history of serious disease and took no
medications for at least four weeks before the study. The
study protocol was approved by the Ethics Committee of
the First Department of Internal Medicine of Hiroshima
University. Written, informed consent for participation was
obtained from all subjects.
Measurement of FBF. Forearm blood flow was measured
using a mercury-filled, strain-gauge Silastic plethysmograph
(EC-5R, D. E. Hokanson, Inc., Issaquah, Washington), as
previously described (5,8,9). Briefly, a strain gauge was
attached to the upper part of the left arm and connected to
a plethysmograhy device and was supported above the right
atrium. A wrist cuff was inflated to 50 mm Hg above the
systolic BP to exclude the hand circulation from the
measurements taken 1 min before measurement of FBF.
The upper arm–congesting cuff was inflated to 40 mm Hg
for 7 s in each a 15-s cycle to occlude venous outflow from
the arm by using a rapid cuff inflator (EC-20, D. E.
Hokanson, Inc., Issaquah, Washington). The FBF output
signal was transmitted to a recorder (U-228, Advance Co.,
Nagoya, Japan). Forearm blood flow was expressed as
ml/min per 100 ml of tissue of forearm volume. Forearm
vascular resistance (FVR) was calculated as the mean BP
divided by FBF and was expressed as a mm Hg/ml/min per
100 ml of tissue of forearm volume.
Study protocol. None of the patients had a history of
antihypertensive treatment before the study. After a four-
week run-in period, first, the pretreatment values of patients
with essential hypertension were compared to those of
normotensive control subjects. Active treatment was then
followed for 48 weeks, and the time courses of the effects of
imidapril and amlodipine were evaluated. Patients were
treated with single daily doses of the ACE inhibitor
imidapril (Tanabe Pharmaceutical Co., Osaka, Japan),
5 mg, or the calcium antagonist amlodipine (Pfizer Phar-
maceutical Co., Tokyo, Japan), 5 mg, in the morning during
the 48-week active treatment period. The patients were
randomly assigned to the imidapril group (n 5 13 [7 men
and 6 women]; mean age 53 6 9 years) or the amlodipine
group (n 5 12 [8 men and 4 women]; mean age 54 6 11
years).
Measurements of FBF were performed at the beginning
of treatment (0 weeks) and after 2, 4, 8, 12, 24 and 48 weeks
of treatment. The study began at 8:30 AM. Subjects fasted
the previous night for at least 12 h. They were kept in the
supine position in a quiet, dark, air-conditioned room
(constant temperature 22°C to 25°C) throughout the study.
Thirty minutes after maintaining the supine position, basal
FBF was measured. Then, the effects of RH and sublingual
NTG on FBF were measured. To obtain RH, FBF was
occluded by inflating the cuff on the left upper arm at a
pressure of 280 mm Hg for 5 min. After the release of
ischemic cuff occlusion, FBF was measured for 3 min.
Nitroglycerin was sublingually administered at the dose of
0.3 mg by one tablet (Nihonkayaku Co., Tokyo, Japan).
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
BP 5 blood pressure
EDHF 5 endothelium-dependent hyperpolarizing
factor
FBF 5 forearm blood flow
FVR 5 forearm vascular resistance
L-NMMA 5 NG-monomethyl-L-arginine
NO 5 nitric oxide
NTG 5 nitroglycerin
RH 5 reactive hyperemia
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After administration of NTG, FBF was measured for
5 min. These studies were carried out in a randomized
fashion. Each study proceeded after FBF had returned to
baseline. In the preliminary study, after the release of cuff
occlusion or sublingual NTG, FBF returned to baseline
within 10 min. Thus, the end of the response to RH or
sublingual NTG was followed by a 15-min recovery period.
Baseline fasting serum concentrations of total cholesterol,
high density lipoprotein cholesterol, triglycerides, creati-
nine, insulin, glucose and electrolytes, as well as plasma
renin activity, were obtained after a 30-min rest period
before the study.
To evaluate the effects of imidapril and amlodipine on
NO release, we measured the FBF response to RH in the
presence of the NO synthase inhibitor NG-monomethyl-L-
arginine (L-NMMA) (CLlNALFA Co., La¨ufelfingen,
Switzerland) in 6 of 13 hypertensive patients treated with
imidapril and in 6 of 12 patients treated with amlodipine
after 12 weeks of treatment. A 23-gauge polyethylene
catheter (Hakkow Co., Yokayama, Japan) was inserted
under local anesthesia (1% lidocaine) into the left brachial
artery for infusion of L-NMMA. After maintaining the
supine position for 30 min, we measured basal FBF. Then,
the effect of RH on forearm hemodynamic data was
measured. After a 15-min recovery period, L-NMMA was
infused intra-arterially at a dose of 8 mmol/min for 5 min
Table 1. Clinical Characteristics in Normotensive Subjects and Patients With Essential Hypertension Treated With the
Angiotensin-Converting Enzyme Inhibitor Imidapril and the Calcium Antagonist Amlodipine Before (0 Weeks) and
After 2, 4, 8, 12, 24 and 48 Weeks
Variable
Normotensive
Subjects
(n 5 25)
Hypertensive Patients
Before Treatment (0 Weeks) After 2 Weeks After 4 Weeks
Imidapril
(n 5 13)
Amlodipine
(n 5 12)
Imidapril
(n 5 8)
Amlodipine
(n 5 10)
Imidapril
(n 5 13)
Amlodipine
(n 5 12)
Body mass index (kg/m2) 23.8 6 2.8 24.1 6 2.7 24.3 6 2.6 25.0 6 3.1 24.2 6 2.9 24.1 6 2.7 24.2 6 2.5
Systolic blood pressure
(mm Hg)
116.4 6 10.2 168.1 6 11.5* 170.3 6 12.6* 150.8 6 10.2*† 144.6 6 10.5*† 146.8 6 9.7*† 143.5 6 9.5*†
Diastolic blood pressure
(mm Hg)
69.1 6 8.8 98.8 6 8.9* 96.6 6 10.8* 96.6 6 8.7* 87.4 6 8.1*†‡ 94.4 6 8.6* 86.1 6 8.5*†‡
Heart rate (beats/min) 68.4 6 8.1 69.3 6 7.3 66.7 6 8.6 70.2 6 7.8 71.2 6 8.9 71.0 6 8.0 72.4 6 8.8
Total cholesterol (mmol/liter) 4.83 6 0.71 5.11 6 0.80 5.04 6 0.78 5.08 6 0.78 5.01 6 0.85 5.01 6 0.74 4.98 6 0.86
Triglycerides (mmol/liter) 1.13 6 0.41 1.20 6 0.48 1.17 6 0.50 1.22 6 0.47 1.14 6 0.39 1.18 6 0.42 1.14 6 0.46
HDL cholesterol (mmol/liter) 1.47 6 0.33 1.45 6 0.43 1.44 6 0.39 1.46 6 0.44 1.45 6 0.36 1.46 6 0.43 1.446 0.42
LDL cholesterol (mmol/liter) 3.12 6 0.58 3.42 6 0.71 3.35 6 0.68 3.37 6 0.69 3.33 6 0.64 3.31 6 0.65 3.30 6 0.69
Serum glucose (mmol/liter) 4.8 6 0.5 4.9 6 0.4 4.8 6 0.4 4.8 6 0.3 4.8 6 0.5 4.9 6 0.5 4.8 6 0.4
FBF (ml/min per 100 ml
tissue)
4.5 6 1.2 4.4 6 1.3 4.6 6 1.4 4.5 6 1.4 4.5 6 1.3 4.4 6 1.4 4.5 6 1.4
FVR (mm Hg/ml/min per
100 ml tissue)
18.8 6 3.7 27.7 6 4.2* 26.4 6 4.1* 25.4 6 3.8*† 23.7 6 3.6*† 25.3 6 3.9*† 23.4 6 3.5*†
Smoker (n) 3 3 2 1 2 3 2
8 Weeks After 12 Weeks After 24 Weeks After 48 Weeks
Imidapril
(n 5 13)
Amlodipine
(n 5 11)
Imidapril
(n 5 13)
Amlodipine
(n 5 12)
Imidapril
(n 5 10)
Amlodipine
(n 512)
Imidapril
(n 5 8)
Amlodipine
(n 5 10)
24.0 6 2.7 24.4 6 2.6 24.0 6 2.7 24.1 6 2.5 24.5 6 3.0 24.2 6 2.6 24.4 6 2.9 24.6 6 2.7
144.3 6 9.8*† 142.6 6 10.2*† 146.1 6 10.1*† 143.3 6 10.3*† 146.3 6 10.5*† 143.1 6 10.2*† 148.8 6 11.2*† 142.9 6 11.1*†
88.2 6 8.4*† 85.2 6 9.4*† 89.0 6 8.8*† 86.1 6 8.9*† 88.0 6 8.9*† 82.8 6 9.0*† 90.2 6 8.7*† 84.2 6 9.5*†
68.1 6 7.9 70.5 6 8.9 70.3 6 7.8 69.8 6 7.9 71.1 6 8.2 68.7 6 8.0 69.8 6 7.9 67.9 6 8.4
5.06 6 0.78 5.03 6 0.84 5.10 6 0.82 4.99 6 0.87 5.06 6 0.76 4.96 6 0.83 5.09 6 0.81 5.02 6 0.90
1.19 6 0.44 1.21 6 0.51 1.10 6 0.40 1.20 6 0.52 1.17 6 0.48 1.22 6 0.53 1.18 6 0.48 1.21 6 0.54
1.44 6 0.39 1.42 6 0.53 1.42 6 0.38 1.40 6 0.48 1.44 6 0.40 1.41 6 0.46 1.43 6 0.41 1.42 6 0.49
3.40 6 0.70 3.39 6 0.72 3.46 6 0.74 3.35 6 0.76 3.39 6 0.70 3.31 6 0.74 3.42 6 0.72 3.36 6 0.78
4.7 6 0.3 4.9 6 0.5 4.6 6 0.4 4.8 6 0.4 4.8 6 0.3 4.7 6 0.5 5.0 6 0.5 4.9 6 0.4
4.3 6 1.3 4.4 6 1.3 4.4 6 1.3 4.5 6 1.4 4.4 6 1.2 4.4 6 1.3 4.5 6 1.4 4.6 6 1.3
24.8 6 4.1*† 24.2 6 4.4* 24.5 6 3.8* 23.4 6 3.9*† 24.4 6 4.0*† 23.9 6 3.8*† 24.3 6 4.1*† 22.8 6 4.2*†
3 2 3 2 1 2 1 2
*p , 0.05 versus normotensive subjects. †p , 0.5 versus hyperpertensive patients before treatment (0 weeks). ‡p , 0.05 versus imidapril (same weeks). All data are presented
as the mean value 6 SD.
FBF 5 forearm blood flow; FVR 5 forearm vascular resistance; HDL 5 high density lipoprotein: LDL 5 low density lipoprotein.
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before FBF measurement. We performed RH after initia-
tion of a 5-min infusion of L-NMMA.
In the preliminary study, we evaluated the effects of oral
administration of imidapril (5 mg/day for 12 weeks) on the
circulating levels of ACE, angiotensin II and bradykinin in
eight patients with essential hypertension (6 men and 2
women; mean age 49 6 10 years). After 12 weeks of
treatment, imidapril significantly decreased serum ACE
activity from 13.1 6 3.1 to 3.9 6 1.1 IU/liter (p , 0.01)
and the plasma angiotensin II level from 17.2 6 8.3 to
4.1 6 1.3 pg/ml (p , 0.01) and increased the plasma
bradykinin level from 15.6 6 4.8 to 24.9 6 13.2 pg/ml (p ,
0.05). We confirmed the reproducibility of RH and sublin-
gual NTG-induced vasodilation twice each month in seven
healthy male subjects (mean age 25 6 4 years). The
coefficients of variation were 4.1% and 2.5%, respectively.
Analytical methods. Samples of venous blood were placed
in tubes containing EDTA-Na (1 mg/ml) and in polysty-
rene tubes. The EDTA-containing tubes were promptly
chilled in an ice bath. Plasma was immediately separated by
centrifugation at 3,100 rpm at 4°C for 10 min, and serum at
1,000 rpm (at room temperature) for 10 min. The samples
were stored at 280°C until assayed. Routine chemical
methods were used to determine serum concentrations of
total cholesterol, high-density lipoprotein cholesterol, tri-
glycerides, creatinine, glucose and electrolytes. The serum
concentration of low density lipoprotein cholesterol was
estimated using Friedewald’s method (22).
Statistical analysis. The results are presented as the mean
value 6 SD. Values of p , 0.05 were considered significant.
The Mann-Whitney U test was used to evaluate the
differences in variables at the baseline between the hyper-
tensive patients and normotensive subjects. Comparisons of
time course curves of variables during RH were analyzed by
two-way analysis of variance (ANOVA) for repeated mea-
sures. The data were processed using either StatView IV
(Brainpower) or Super ANOVA (Abacus Concepts).
RESULTS
Clinical characteristics of normotensive subjects and
hypertensive patients. The baseline clinical characteristics
of the 13 hypertensive patients treated with imidapril, 12
hypertensive patients treated with amlodipine and 25 nor-
motensive subjects are shown in Table 1. The systolic and
diastolic BPs, as well as FVR, were significantly higher in
the hypertensive patients than in the normotensive subjects.
These variables were similar between the imidapril and
amlodipine groups. Body mass index, lipid metabolism,
serum glucose and the prevalence of smoking were similar
among the three groups.
Reactive hyperemia in normotensive subjects and hyper-
tensive patients. The FBF of the patients with essential
hypertension in response to RH, an index of endothelium-
dependent vasorelaxation, was significantly smaller than
that of normotensive subjects, whereas the baseline FBF was
similar between the two groups (Fig. 1).
The increase in the FBF after sublingual administration
of NTG, an index of endothelium-independent vasodila-
tion, was similar between the normotensive subjects and
hypertensive patients (Fig. 2).
Effects of imidapril and amlodipine on clinical charac-
teristics. The effects of imidapril and amlodipine on base-
line variables are shown in Table 1. Imidapril significantly
reduced systolic BP after two weeks of treatment and
diastolic BP after eight weeks of treatment, compared with
baseline values (0 weeks). Amlodipine significantly reduced
systolic BP and diastolic BP after two weeks of treatment,
compared with baseline values. The BP-lowering effects of
Figure 1. Line graphs show forearm blood flow at rest and during reactive
hyperemia in patients with essential hypertension and in normotensive
control subjects. Reactive hyperemia was impaired in hypertensive patients
compared with normotensive subjects.
Figure 2. Bar graphs show maximal forearm blood flow after sublingual
administration of nitroglycerin (NTG) in patients with essential hyperten-
sion and in normotensive control subjects. The NTG-induced vasodilation
was similar between the two groups.
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imidapril and amlodipine were maintained throughout the
48-week treatment period. Heart rate was not significantly
modified by imidapril or amlodipine for each treatment
period. Both imidapril and amlodipine significantly de-
creased FVR after two weeks of treatment. Serum levels of
lipids and glucose were similar for all treatment periods
between the two groups.
Effects of imidapril and amlodipine on RH. The effects
of imidapril and amlodipine on endothelial function before
and after 2, 4, 8, 12, 24 and 48 weeks of treatment in
patients with essential hypertension are shown in Figure 3.
Imidapril significantly augmented RH after 12 weeks of
treatment, compared with the pretreatment value (0 weeks)
(p , 0.001). The ability of imidapril to improve RH was
maintained throughout the 48-week treatment period.
There was no significant difference in RH after 12, 24 and
48 weeks in the imidapril group. Although imidapril tended
to augment RH after the four- and eight-week treatment
periods, this effect did not reach statistical significance.
Amlodipine did not alter RH for each treatment period.
The increase in FBF after sublingual administration of
NTG was similar for all treatment periods between the two
groups (Fig. 4).
Effects of L-NMMA on RH. Intra-arterial infusion of
L-NMMA reduced basal FBF from 4.6 6 1.3 to 2.5 6
0.5 ml/min per 100 ml tissue in the imidapril group and
from 4.4 6 1.3 to 2.4 6 0.4 ml/min per 100 ml tissue in the
amlodipine group (p , 0.05, respectively) and abolished the
augmentation of the FBF response to RH in patients
treated with imidapril (p , 0.001). L-NMMA reduced RH
in the amlodipine group (p , 0.001). After L-NMMA
infusion, RH was similar between the two groups (Fig. 5).
L-NMMA infusion did not alter arterial BP or heart rate in
any group.
DISCUSSION
The present study confirmed the previous findings that the
resistance vessels’ endothelial function was impaired in
patients with essential hypertension, compared with normo-
tensive control subjects, and demonstrated that $12 weeks
of treatment with the ACE inhibitor imidapril augmented
RH of the forearm artery in patients with essential hyper-
tension.
In the present study, RH, an index of endothelium-
dependent vasodilation, was smaller in patients with essen-
tial hypertension than in normotensive subjects, whereas
the forearm vascular response to NTG, an index of
endothelium-independent vasodilation, was similar between
the two groups. Our results are consistent with previous
studies indicating that endothelium-dependent vasodilation
of brachial (8–11), renal (5–7,12) and coronary (23) arteries,
as well as small arteries (13), was impaired in patients with
essential hypertension, compared with normotensive sub-
jects. These findings suggest that the vascular endothelium,
but not smooth muscle cells, was selectively impaired in
patients with essential hypertension.
Several lines of evidence from experimental (16–18) and
clinical studies (11–15,24) indicate that ACE inhibitors can
restore endothelial function in hypertension. In the present
study, $12 weeks of treatment with imidapril augmented
RH in the forearm microvascular circulation of patients
with essential hypertension. Our findings are supported by
the results of most studies that up to 12 weeks of treatment
with ACE inhibitors improves endothelial function in
patients with essential hypertension (Higashi et al. [14]; in
the renal artery, for 12 weeks, Iwatubo et al. [11] and
Higashi et al. [15]; in the brachial artery, for 24 weeks,
Mimran et al. [12]; in the renal artery, and Schiffrin et al.
[13]; in the small arteries, for two years). These findings
suggest that antihypertensive treatment with ACE inhibi-
tors requires at least 12 weeks to restore resistance artery
endothelial function. In addition, we confirmed that im-
provement of the endothelial function of the resistance
Figure 3. Line graphs show forearm blood flow at rest and during reactive
hyperemia in patients with essential hypertension before (0 weeks) and
after 2, 4, 8, 12, 24 and 48 weeks of treatment with the angiotensin-
converting enzyme inhibitor imidapril and the calcium antagonist amlo-
dipine. Imidapril augmented RH after 12 weeks of treatment. There was
no significant difference in RH at 12, 24 and 48 weeks. Amlodipine did not
alter RH for each treatment period.
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artery by ACE inhibition was maintained from 12 to 48
weeks after treatment. However, Creager et al. (21) showed
that clinically effective antihypertensive therapy with ACE
inhibitors for up to seven to eight weeks did not restore
impaired endothelium-dependent vasodilation in the fore-
arm circulation. Discrepancies in the reports from their
laboratories may be due to the severity of hypertension in
selected patients and to differences in the method of
assessing endothelial function and the treatment periods.
Mechanisms. Several possible mechanisms by which ACE
inhibitors augment RH in patients with essential hyperten-
sion were postulated. First, a balance between angiotensin II
and NO plays an important role in the regulation of vascular
tone (19). Angiotensin II increases vascular superoxide
production through activation of membrane-associated
NADH/NADPH oxidase, resulting in inactivation of NO
and production of toxic peroxynitrite (19). Therefore, ACE
inhibitors may relatively increase NO by the inhibition of
angiotensin II production. Second, endogenous bradykinin
is limited by ACE under physiologic conditions. Bradykinin
binds to B2 receptors on the endothelial cell surface to
release NO (20). Angiotensin-converting enzyme inhibitors
inhibit the degradation of bradykinin, resulting in increased
NO release.
Taddei et al. (25) showed that one-year treatment with
the ACE inhibitor lisinopril augmented the FBF response
to bradykinin, but not that to acetylcholine, in hypertensive
patients, in line with the results of Creager et al. (21). These
findings suggest that ACE inhibitors may selectively facil-
itate the activation of bradykinin B2 receptors, but not that
of other receptors such as the muscarinic receptor, most
likely through the inhibition of bradykinin degradation,
leading to the accumulation of bradykinin within the
vascular endothelium. Recently, Horning et al. (26) showed
that shear stress-induced release of bradykinin may be
especially augmented by ACE inhibitors. Taken together,
we can hypothesize that the increase in the concentration of
endogenous bradykinin by RH-induced shear stress may
contribute to the augmentation of the FBF response to RH
after treatment with the ACE inhibitor imidapril.
Reactive hyperemia may be mediated by many factors,
such as NO, prostaglandin, EDHF and ischemia-induced
adenosine release. In the present study, L-NMMA abol-
ished RH by ;50% before ACE inhibitor treatment (Fig.
5). We have previously shown that ACE inhibitor-induced
enhancement of RH was not affected by a prostaglandin
synthesis inhibitor, suggesting that prostaglandin does not
contribute to the beneficial effects of ACE inhibitors on
forearm resistance artery endothelial function in patients
with essential hypertension (15). The inhibited degradation
of bradykinin induced by ACE inhibition has been shown
to increase EDHF (27). This vasodilating factor contributes
to the augmentation of RH. However, because enhanced
RH by imidapril was inhibited substantially by L-NMMA,
the increase in NO release may be involved in imidapril-
enhanced RH in patients with essential hypertension.
Interestingly, in the present study, the hypotensive effect
of the ACE inhibitor imidapril preceded the restoration of
FBF response to RH. In addition, although the calcium
antagonist amlodipine was equally effective in reducing BP,
RH was greater in the imidapril group than in the amlo-
dipine group. These findings suggest that improvement of
endothelial dysfunction may not contribute to the mecha-
nism that reduces in BP in patients with essential hyper-
tension. In contrast, there is a possibility that the reduction
in BP, per se, may result in improvement of endothelial
dysfunction. Several investigators, including ourselves, have
reported that ACE inhibitors, but not calcium antagonists
or beta-blockers, improve endothelial dysfunction, although
all of these drugs have equivalent hypotensive effects (11–
Figure 4. Bar graphs show maximal forearm blood flow after sublingual administration of nitroglycerin (NTG) in patients with essential hypertension before
(0 weeks) and after 2, 4, 8, 12, 24 and 48 weeks of treatment with the angiotensin-converting enzyme inhibitor imidapril and the calcium antagonist
amlodipine. The NTG-induced vasodilation was similar for all treatment periods.
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15). Because the reduction in BP by effective antihyperten-
sive therapy, per se, may not always be accompanied by
improvement of endothelial dysfunction in patients with
essential hypertension, this possibility is unlikely.
Study limitations. The use of agonists to stimulate NO
release, such as acetylcholine or bradykinin, allows us to
draw more specific conclusions concerning the role of basal
and stimulated release of NO by antihypertensive agents in
the forearm circulation. In addition, the use of a bradykinin
B2 receptor antagonist demonstrates more specific conclu-
sions concerning the role of bradykinin-stimulated release of
NO by the ACE inhibitor imidapril. Recently, we have
demonstrated that noninvasive methods, such as RH, are
useful for assessing the resistance vessels’ endothelial func-
tion, instead of the method of infusion of intra-arterial
vasoactive agents (28). Indeed, because this noninvasive
technique is simple and reproducible and does not cause
adverse effects, it can be used for routine clinical examina-
tions in the future.
We have previously confirmed that NO plays an impor-
tant role in the augmentation of RH in hypertensive
patients receiving ACE inhibitors, including imidapril, over
24 weeks (15). In the present study, the FBF responses to
RH augmented by imidapril were similar among the 12-,
24- and 48-week treatment periods. Therefore, the same
mechanism may continue at later time points, as well as at
12 weeks. In contrast, not only the endothelial function of
peripheral arteries, but also structural changes in the periph-
eral arteries can affect the FBF response to RH. However, in
the present study, the response of FBF to NTG was not
changed by the ACE inhibitor imidapril. Therefore, it is
unlikely that structural changes in the peripheral arteries
were caused by imidapril.
Conclusions. The forearm vascular response to RH was
impaired in patients with essential hypertension, compared
with normotensive subjects. Twelve or more weeks of
treatment with imidapril restored the resistance vessels’
endothelial function in the forearm circulation in patients
with essential hypertension.
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